Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial.

@article{Jegatheesan2008IncreasedID,
  title={Increased indomethacin dosing for persistent patent ductus arteriosus in preterm infants: a multicenter, randomized, controlled trial.},
  author={Priya Jegatheesan and Vlad Ianus and Basharat N Buchh and Grace Yoon and Nancy Chorne and Audrey Ewig and E Gin Lin and Scott Fields and A J Moon-Grady and Terri Tacy and Jay M. Milstein and Michael Schreiber and James Padbury and Ronald Clyman},
  journal={The Journal of pediatrics},
  year={2008},
  volume={153 2},
  pages={183-9}
}
OBJECTIVE We conducted a multicenter, randomized, controlled trial to determine whether higher doses of indomethacin would improve the rate of patent ductus arteriosus (PDA) closure. STUDY DESIGN Infants (<28 weeks gestation) who received a conventional, prophylactic 3-dose course of indomethacin were eligible if they had continued evidence of persistent ductus patency on an echocardiogram obtained before the third prophylactic indomethacin dose. Infants (n = 105) were randomized to receive… CONTINUE READING